A recent study suggests that patients who come off blockbuster GLP-1 drugs like Wegovy and Mounjaro can put back on reduced body mass at a significantly accelerated pace than those who end traditional diet and exercise programs.
Findings released in a leading medical journal points out that while overweight individuals frequently drop substantial amounts of their total mass while on the medication, the weight returns at an average rate of 0.8 kg per month once they quit.
"Users buying these treatments should be cognizant of the potential of rapid rebound weight gain when the therapy concludes," cautioned lead investigator Dr. Susan Jebb.
This pace of regain suggests a return to original mass within about one and a half years.
Analyzing Approaches
The analysis, which reviewed dozens of studies involving over 9,000 of patients, contrasted the effects of these new drugs with conventional dieting.
Scientists note that individuals who shed pounds through diet and exercise usually experience a less rapid creep back—perhaps 0.1 kg a month—after stopping.
Understanding the Fast Rebound
Nutrition scientists suggest the mechanism of the jabs explains the accelerated rebound.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of GLP-1 concentrations several times higher than normal could lead to the body to generate a reduced amount of its own natural GLP-1, and may also reduce sensitivity to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this medication results in appetite is no longer kept in check, making overeating a significant risk."
A Chronic Condition?
Health authorities suggest the injections for people with weight-linked health risks, alongside prescribed diet and exercise modifications.
Many experts say that, due to the high risk of weight regain, the treatment might need to be life-long.
This view is supported by drug manufacturers, who note that the findings "highlight the long-term nature of excess weight," comparing it to managing conditions like high blood pressure.
User Experiences
Users who have stopped the jabs explain a intense return of hunger.
"It was like a trigger that goes on and I was suddenly ravenous," recalled a patient.
This difficulty is exacerbated if users have not established permanent dietary or behavioural changes during treatment.
Significant Use
Survey data suggest that millions of people in the UK have used these injections in the past year, with desire continuing to grow.
- Adoption is greater among females compared to males.
- The 40s and 50s age group shows the greatest level of interest.
- Many access the drugs through private prescriptions rather than the NHS.
Finally, clinicians emphasize that while the jabs are powerful agents for weight loss, they are not a magic solution and maintained weight loss hinges on combined lifestyle support.
